That's a nicer more optimistic read on numbers nilla. Always a number of ways to crunch the numbers.
I had the exact same question a few weeks ago and Kevinmlk told me that the submission to the FDA was in December of 2014 and that it was a 6month review. So that would put us in June.
I've never been more convinced of the success we are going to have than I am today after Amy Tenderich got behind afrezza. She is an objective third party with no agenda other than helping diabetes treatment. Frankly due to some annoying MNKD investors I think she would have loved to pan Afrezza, but her results spoe for themselves and she is behind this product. God love Afrezzauser and Peakabull for their efforts, and I appreciate it so much but they have skin in the game and that always leaves me skeptical. Amy's feedback is the best early adopter data yet.
Afrezza has worked in early adopters EXACTLY as Al Mann promised, demonstrating activities that the clinical trial was not designed to capture. 1) Reversal of insulin insensitivity 2) Greatly improved fasting blood glucose. I cant wait to hear about the A1C's our early adopters are going to report.
Lilly paid Adocia 1B for a injected insulin that improves peak concentration by seven minutes 38min vs 45min. Afrezza is hands down the best insulin on the market by light years and its success is assured by science. Good luck all longs.
Great post..... my money is that the FUD announcement that SNY is dropping Afrezza.... only to be followed by buyout announcement. They have been laying the groundwork for this FUD already.
I agree with reality 100%! IMHO this was part of the reason for the controlled launch. They wanted to wait for Toujeo so they could market them together to Type1 patients.
They don't want people to know how much success they can have with Lantus + Afrezza.
Toujeo + Afrezza will be marketed as the safest and most effective treatment on the market because it actually will be.
I agree and you are correct. IMHO I believe he stepped down because he feels his work with MNKD is done. He has put a vastly improved treatment for Diabetes on the market..... the rest will take care of itself.
Now he seeks to cure blindness. On to the next great challenge of his life. Amazing man, scientist, business man, human being.
I initially got into MNKD because I knew scientifically that they had, by orders of magnitude, the best insulin on the market.
Initial user feedback is proving that this is true, and that all the things we suspected are in fact true. 1) FDA protocol prevented superior A1C data in trials. 2) Afrezza is truly ultra-rapid acting as advertised by Al et. al. 3) Non-diabetic numbers are achievable with Afrezza.
You will recall that aggressive monitoring and treatment with R.A.A's to achieve A1C's below 6 were abandoned and found to be harmful to patients, because the only way you can do this with RAA's is to have patients hypo too much.
The real world experiences relayed by Afrezzauser, peakabull, and Adam are amazing and clearly show that we indeed are on the cusp of a paradigm shift.
I bought yesterday and I will buy again at these levels as soon as funds clear. Good luck longs.... you won't need it.... science is on your side.
IMHO the 12U cartidge approval will be accompanied by a strong push in the Type II market. TII's are much more likely to be insulin insensitive and require much larger doses of Afrezza.
Agree 100% akemp3000 nice post. I have been of the mind that the secondary launch is all about the 12U cartridge being needed for a strong push in TII, and that the Toujeo Afrezza combination is what they are waiting for to strongly push in TI. The combination (both having lower hypo risk) is the safest and best treatment on the market, and that's what they are going to push.
They didn't really want people to have too much success with Afrezza + Lantus. They want everyone to switch to Toujeo + Afrezza.
The big players know they will cover before retail. They are happy to bait retail shorts to pile on. Retail shorts will simply add fuel to the fire when they finally decide to cover too late of course.
Let's be realistic. The short position is currently over-weight foaming at the mouth and ready to get spit roasted. Greedy longs and shorts get slaughtered all the same. Shorts are well past greedy at this point.
I have to ask. With all the speculation about fake reviews being put forward why is it that there are no negative comments? Shorts with their self proclaimed higher trading IQ's could I'm sure pen a believable negative comment could they not? Why then are there none? Is there a better screening procedure than we believe?